|
| Product Name: | yk11 | | Synonyms: | YK-11-OA;(17alpha,20E)-17,20-[(1-Methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester;YK11 YK11 white powder;High quality 1370003-76-1 Sarms YK11 CAS NO.1370003-76-1 Manufacturers wholesale;YK11;YK 11;Factory supply with low price Sarms YK11 99% YK-11 in stock CAS NO.1370003-76-1;YK-11 (Mixture of diasteromers);Hot sell | | CAS: | 1370003-76-1 | | MF: | C25H34O6 | | MW: | 430.53 | | EINECS: | 1532714-185-1 | | Product Categories: | 1370003-76-1 | | Mol File: | 1370003-76-1.mol |  |
| Melting point | 134-137°C | | Boiling point | 564.4±50.0 °C(Predicted) | | density | 1.22±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Solid | | color | White to Pale Yellow | | InChIKey | KCQHQCDHFVGNMK-PQUNLUOYSA-N |
| Description | YK11 was first studied by Japanese researcher Yuichiro Kanno in 2011. It was found to be a partial agonist of the androgen receptor (AR), genetically selective, leading researchers to believe the compound was a SARM. YK11 is an experimental drug candidate and an unapproved substance for use in humans. | | Uses | YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM).It is a gene-selective partial agonist of the androgen receptor (AR) and does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR. | | Mechanism of action | YK-11 is an androgen receptor partial agonist that activates androgen receptor transcriptional activity in HEK293 cells overexpressing androgen receptors when used at a concentration of 0.1 μM.1 It induces expression of the androgen receptor target genes FKBP51 and FGF18 in HEK293 cells when used at a concentration of 10 μM. YK-11 accelerates nuclear translocation of androgen receptors without inducing interaction between the androgen receptor N- and C-termini. In C2C12 cells, YK-11 (500 nM) increases expression of the myogenic regulatory factors MyoD, Myf5, and myogenin, as well as follistatin (Fst), and induces myogenic differentiation. | | References | [1] Yuichiro Kanno, et al. Exp Cell Res. Differential DNA-binding and cofactor recruitment are possible determinants of the synthetic steroid YK11-dependent gene expression by androgen receptor in breast cancer MDA-MB 453 cells DOI:10.1016/j.yexcr.2022.113333
[2] Su Jin Lee, et al. Biochem Biophys Res Commun. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis DOI:10.1016/j.bbrc.2021.01.030
[3] Tomofumi Yatsu, et al. Biol Pharm Bull. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells DOI:10.1248/bpb.b17-00748
[4] Mario Thevis, et al. Mol Cell Endocrinol. Detection of SARMs in doping control analysis DOI:10.1016/j.mce.2017.01.040
[5] Yuichiro Kanno, et al. Biol Pharm Bull. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression DOI:10.1248/BPB.B13-00231 |
| | yk11 Preparation Products And Raw materials |
|
